Close
Smartlab Europe
Achema middle east

Clinical Trials

CyanVac Selects Exothera for the Development and GMP Mfg anufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and...

CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector. Exothera...

Phase 3 Trial Shows REGEN-COV antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

Regeneron Pharmaceuticals, Inc. announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing...

BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, announced that it has commenced a Phase 2 clinical trial of BGE-175, a potent oral inhibitor of prostaglandin D2(PGD2) DP1 signaling with a...

Accenture and Phesi urges pharmaceutical companies to make use of synthetic data in clinical trials

Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, and Accenture, a global services and consulting company with leading capabilities in digital, cloud, and security, have released the first of a series of reports exploring...

CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine...

Moderna starts Phase I study of new Covid-19 vaccine candidate

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children...

TrialScope Welcomes Alexion to Its Growing Clinical Trial Disclosure Community

TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers. Alexion joins the ranks of other industry leaders that rely on TrialScope Disclose™ to help manage global clinical trial...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »